Original Article



Electroconvulsive therapy response and remission in moderate to severe depressive illness: a decade of national Scottish data

David M. Semple, Szabolcs Suveges and J. Douglas Steele

Background

Despite strong evidence of efficacy of electroconvulsive therapy (ECT) in the treatment of depression, no sensitive and specific predictors of ECT response have been identified. Previous metaanalyses have suggested some pre-treatment associations with response at a population level.

Aims

Using 10 years (2009–2018) of routinely collected Scottish data of people with moderate to severe depression (n = 2074) receiving ECT we tested two hypotheses: (a) that there were significant group-level associations between post-ECT clinical outcomes and pre-ECT clinical variables and (b) that it was possible to develop a method for predicting illness remission for individual patients using machine learning.

Method

Data were analysed on a group level using descriptive statistics and association analyses as well as using individual patient prediction with machine learning methodologies, including cross-validation.

Results

ECT is highly effective for moderate to severe depression, with a response rate of 73% and remission rate of 51%. ECT response is

Depressive illness remains one of the most important world health problems, with an estimated 264 million people of all ages currently affected.¹ The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study confirmed that despite existing anti-depressant and psychotherapeutic treatments, a large proportion of patients have a chronic (25%) or recurrent (75%) illness course.² Depressive illness is usually resistant to treatment, as most people do not reach remission with their first treatment trial, indicated by treatment effectiveness studies reporting that only 11–30% of patients achieve remission, even after 8–12 months of treatment.² Unfortunately, for those who do achieve remission, symptom relapse occurs in 10–45%.² Further research is a priority to identify more effective treatment strategies.

For people unresponsive to antidepressants and psychotherapy, two large meta-analyses have concluded that electroconvulsive therapy (ECT) is the most effective treatment for moderate to severe depressive illness,^{3,4} resulting in a good return to health-related quality of life and function.⁵ These meta-analytic findings for the effectiveness of ECT are confirmed by published reports from organisations that monitor ECT in the UK: the Electroconvulsive Therapy Accreditation Network (ECTAS)⁶ and the Scottish ECT Audit Network (SEAN).⁷ However, although there is consensus on efficacy, there is less consensus on sensitive and specific predictors of ECT response⁸ to inform clinical decision-making.

Since most studies are small and heterogeneous, meta-analytic approaches have been used. A recent systematic review and metaanalysis of 34 studies reporting on 3276 people with a depressive disorder treated with ECT concluded that, for major depression, older age and psychotic features were significant predictors of both associated with older age, psychotic symptoms, necessity for urgent intervention, severe distress, psychomotor retardation, previous good response, lack of medication resistance, and consent status. Remission has the same associations except for necessity for urgent intervention and, in addition, history of recurrent depression and low suicide risk. It is possible to predict remission with ECT with an accuracy of 61%.

Conclusions

Pre-ECT clinical variables are associated with both response and remission and can help predict individual response to ECT. This predictive tool could inform shared decision-making, prevent the unnecessary use of ECT when it is unlikely to be beneficial and ensure prompt use of ECT when it is likely to be effective.

Keywords

Electroconvulsive therapy; depressive disorder; efficacy; machine learning; prediction.

Copyright and usage

© The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists.

ECT remission and response, pre-ECT severity of depression predicted response but not remission, and data on melancholic symptoms were inconclusive.⁹

However, research studies usually have inclusion and exclusion criteria, so may not reflect routine clinical practice. Consequently, routinely collected clinical audit data, acquired over many years using standardised methods at a national level, may provide the best available information on ECT clinical practice. In Scotland, all centres providing ECT have to be registered with SEAN, providing clinical audit information, with descriptive data published annually in reports by Public Health Scotland.¹⁰ This data-set provides a unique opportunity to examine possible clinical associations with ECT outcome and explore possible predictive modelling.

Aims

Using 10 years of national Scottish ECT data collected by SEAN, we tested two hypotheses. First, that that there were significant group-level associations between post-ECT clinical outcomes and clinical variables available before starting a course of ECT treatment. Second, that it was possible to develop a new method for predicting illness remission for individual patients using machine learning.

Method

SEAN data 2009-2018

Anonymised SEAN audit data for the period 2009–2018 were provided by the Scottish National Audit Programme (SNAP) of Public

Health Scotland. Release of the data was approved by the SEAN steering group (SEAN reference: IR2022-00182) for all ECT treatment episodes in Scotland for 2009–2018, comprising 4474 individual treatment records (some patients will have had more than one treatment). National audit data are anonymised by SEAN staff before release to researchers, meaning that approval by the National Research Ethics Service was not required, confirmed by use of the NHS Human Research Authority online decision tools (www.hra-decisiontools.org.uk/) and following discussion with the local senior research and development facilitator.

SEAN data stratification and coding

Data were stratified by primary diagnosis coded according to ICD-10.¹¹ The available SEAN data comprised depressive disorder or recurrent depressive disorder (n = 3307), bipolar disorder (n = 605), postnatal depression (n = 51), schizophrenia and related primary psychoses (n = 270), neurotic or related disorders (n = 58), personality disorders (n = 10), organic disorders (n = 8) and no specific diagnosis recorded (n = 165). Our primary interest was determining whether it was possible to predict response to ECT in the acute unipolar depressive illness group with moderate to severe illness, so SEAN data were first filtered to include only cases of depressive disorder or recurrent depressive disorder for which entry and exit Montgomery–Åsberg Depression Rating Scale (MADRS) scores were recorded, reducing the total number of data records (n = 2230). SEAN data codes are detailed in Table 1.

This group included patients who were receiving continuation ECT treatment and typically had low entry Clinical Global Impression-Severity (CGI-S) and depression severity scores. As our primary interest was specifically in the efficacy of ECT in acute unipolar depressive episodes, rather than maintenance ECT, we further filtered the data to include only moderate to severe depressive episodes with or without psychotic symptoms.

Table 1 Scottish ECT Accreditation	n Network (SEAN) data-set codes and descriptions
SEAN data-set code	Description
'Pre-ECT variables' – information	available before ECT treatment course
Age_years_at_episode	Age in years at episode start
Female	Gender (0 = Male; 1 = Female)
Capacity_Consent	Combined data item reflecting capacity and consent status ($1 = Capable - informal; 2 = Capable - T2; 3 = Incapable - s48;$
	4 = Incapable - T3A; $5 = Incapable - T3B$; $6 = Incapable - urgent$; $7 = Not known$
Informal	Simplified legal status (1 = informal 0 = formal)
DiagnosisICD10	Diagnosis ICD-10 full code
DiagnosisICDshort	Diagnosis ICD-10 three-digit code
PsychoticSx	Psychotic symptoms noted in ICD-10 coding ($0 = No; 1 = Yes$)
RecurrentDD	Depressive illness recorded as recurrent as defined by ICD-10 ($0 = No; 1 = Yes$)
Measures of clinical symptoms	
CGIEntry	CGI score at entry (1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 =
	Severely ill; 7 = Extremely ill)
MADRSEntry	Total MADRS score at entry (range 0–60)
MEn1–MEn10	Individual components of MADRS score on entry (range 0–6): MEn1 – Apparent sadness; MEn2 – Reported sadness;
	MEn3 – Inner tension; MEn4 – Reduced sleep; MEn5 – Reduced appetite; MEn6 – Concentration difficulties; MEn7 –
	Lassitude; MEn8 – Inability to feel; MEn9 – Pessimistic thoughts; MEn10 – Suicidal thoughts
Indications for treatment	
IndEmergency	Emergency lifesaving ($0 = No; 1 = Yes$)
IndDistressed	Too distressed to await response to medication $(0 = No; 1 = Yes)$
IndSevereRetard	Severe psychomotor retardation; agitation ($0 = No; 1 = Yes$)
IndSuicide	Suicidal ideation ($0 = No; 1 = Yes$)
IndPsycot	Psychotic ideation $(0 = No; 1 = Yes)$
IndMedResis	Medication resistance $(0 = No; 1 = Yes)$
IndMedResis1	Specific medication resistance – antidepressants ($0 = No; 1 = Yes$)
IndMedResis2	Specific medication resistance – antipsychotics ($0 = No$; $1 = Yes$)
IndMedResis3	Specific medication resistance – mood stabilisers ($0 = No; 1 = Yes$)
IndPatPref	Patient preference $(0 = No; 1 = Yes)$
IndGoodResp	Previous good response to ECT ($0 = No; 1 = Yes$)
'Post-ECT variables'	
Information available after first t	wo ECT treatments
CGI-I2	CGI score after two treatments (1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5
	= Minimally worse; 6 = Much worse; 7 = Very much worse)
Information available at the end	of ECT treatment course
Measures of clinical symptoms	
CGIExit	CGI score at exit (1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally
	worse; 6 = Much worse; 7 = Very much worse)
MADRSExit	Total MADRS score at exit (range 0–60)
MEx1-MEx10	Individual components of MADRS score on entry (range 0–6): MEx1 – Apparent sadness; MEx2 – Reported sadness;
	MEx3 – Inner tension; MEx4 – Reduced sleep; MEx5 – Reduced appetite; MEx6 -Concentration difficulties; MEx7 –
	Lassitude; MEx8 – Inability to feel; MEx9 – Pessimistic thoughts; MEx10 – Suicidal thoughts
MADRSPercentageImprovement	MADRS percentage improvement between exit and entry (negative indicates deterioration)
MADRSChange	MADRSEntry minus MADRSExit
MADRSRemission	Remission defined as MADRSExit score of 10 or less $(0 = No; 1 = Yes)$
MADRSResponder	Response defined as 50% or more improvement in MADRSEntry score ($0 = No; 1 = Yes$)
Information on ECT treatments	Number of tractments in oniondo
TreatmentsTotal	Number of treatments in episode
EpisodeDoseTotal	Total treatment dose (in millicoulombs) for episode
	Average treatment dose (in millicoulombs) for episode
ECT, electroconvulsive therapy; CGI, Clinical	Global Impression scale; CGI-I, Clinical Global Impression-Improvement scale; MADRS, Montgomery-Åsberg Depression Rating Scale.

Depression severity was graded by the entry (baseline pre-ECT) MADRS score.¹² By convention, MADRS scores ≤ 8 indicate absence of depressive symptoms (scores ≤ 10 indicate remission in many outcome studies), scores of 9–17 indicate mild depression, 18–34 moderate depression, and 35–60 severe depression.¹³ Cases with a MADRS entry score of ≤ 17 (mild or absent symptoms) were excluded from analyses, resulting in a final sample size of 2074 (n = 1015 with single-episode depression; n = 1059 with recurrent-episode depression) for acute episodes of illness.

Individual MADRS item scoring included scores recorded pre-ECT course (MEn1-MEn10) and post-ECT course (MEx1-MEx10). The 10 MADRS items coded (with a score of 0-6) were: (1) apparent sadness, (2) reported sadness, (3) inner tension, (4) reduced sleep, (5) reduced appetite, (6) concentration difficulties, (7) lassitude, (8) inability to feel, (9) pessimistic thoughts and (10) suicidal thoughts. Although ethnicity was recorded in 3186 cases in the original depressive disorder group, in 3105 cases (97.5%) it was coded as 'Caucasian', so ethnicity was not included as a covariable in the analyses. We had specifically requested SEAN to include a clinical rating of early improvement, in the form of a Clinical Global Impression-Improvement (CGI-I) score recorded by the responsible consultant after two ECT treatments (CGI-I2), which to our knowledge has not been reported in previous studies, but here was available for 1538 patients.

Statistical analyses

Individual patient-focused decision-making has always been central to psychiatry and other medical specialties. Clinical research recognises this priority, focusing increasingly on 'personalised medicine'. Importantly though, group-level association measures (e.g. linear regression, logistic regression, correlation, odds ratios) are insufficient to establish a claim for individual patient predictions.^{14–16} Unfortunately, the term 'prediction' is often incorrectly used in studies when only association statistics have been reported in psychiatry^{14,15} and other medical specialties.¹⁶ We report both types of analysis. Descriptive and association analyses used JASP (version 0.19)¹⁷ and machine learning prediction analyses used NeuroMiner (version 1.2)¹⁸ both running on Linux Mint 21.2 Cinnamon operating system.

Group level association analyses

The aim was to determine whether SEAN-recorded clinical indications for ECT and other clinical characteristics of patients ('pre-ECT variables') were associated, at a group level, with measures of response and remission ('post-ECT variables') (variables are defined in Table 1). We tested for associations with each pre-ECT variable separately because combinations of 'independent' pre-ECT variables can interact if they are correlated. The advantage of this approach is that it facilitates comparison with previous reports. Tests of associations with the post-ECT continuous variable MADRSexit used simple linear regression, and for the post-ECT dichotomous variables MADRSRemission and MADRSResponder, simple logistic regression was used. Significance was defined as P < 0.05. No correction for multiple testing was done because these were *a priori* planned tests of pre-ECT clinical variables collected by SEAN, selected because they have long been considered relevant to ECT, as summarised in Table 1.

Individual patient prediction analyses

Here the aim was to determine whether it was possible to generate a predictive model of remission for individual patients, as persisting symptoms are strongly associated with relapse.¹⁹ In contrast to the association analyses, all pre-ECT variables were used as potential predictor variables, with the aim of identifying the most accurate

predictive model for remission at an individual patient level, despite the already high efficacy of ECT for selected patients. Missing data can adversely affect machine learning²⁰ so only complete patient data-sets were used. Two predictive model analyses were explored. The first (model 1) used only clinical variables available before starting a course of ECT. The second (model 2) included the CGI-I2 score, as this is available early, at the end of the first week of a course of ECT.

For both predictive analyses, machine learning with cross-validation (within-study replication) was used, resulting in quantification of individual patient predictive accuracy, sensitivity, specificity, receiver operating curve (ROC) and area under the curve (AUC). We followed recommended best practice for reporting evidence for prediction in psychiatry:¹⁴ in-sample fits are not reported as evidence, cross-validation encompassed all data operations, prediction analyses did not include groups smaller than a few hundred samples, the coefficient of determination was calculated using the sum of squares, and k-fold cross-validation was used rather than leave-one-out cross-validation.

Results

Descriptive statistics

The data were for 2074 treatment episodes. The mean age of patients at the time of treatment was 59.44 years (s.d. = 15.67) with a range of 15–96 years. The male to female ratio was 1:1.94, the average MADRS entry (pre-ECT baseline) score was 38.8 (s.d. = 8.6; median 39.0, mode 42.0, range 18–60). The post-ECT MADRS mean score was 13.6 (s.d. = 11.7; median 10.0, mode 0). The difference between the mean and median or mode indicates a strong right skew to the post-ECT MADRS scores, with most patients having an exit MADRS score in the 0–5 range (Table 2).

Most patients (68%) were treated informally, that is fully consenting and not subject to the Scottish Mental Health Act or Adults with Incapacity legislation. The overall incidence of depression with psychotic symptoms was 34%, and the incidence of recurrent depression was 51%. For the two sub-types of depressive illness, the incidence of psychotic symptoms was 30% in recurrent depression and 38% in single-episode depression. Where indications for ECT had been stated, 8% of treatment episodes were performed as an emergency, 28% for severe distress, 24% for severe psychomotor retardation or agitation, 26% for clinically concerning suicidal ideation, 23% for psychotic symptoms and 62% for medication resistance, mostly to antidepressants (61%), but also antipsychotics (24%) and mood stabilisers (13%). These indications overlap as some patients had more than one indication for treatment.

Data were not available on electrode placement, although it is common practice in Scotland to treat with bilateral rather than unilateral electrode placement. The average number of ECT treatments per patient was 9.1 (s.d. = 5.3; mean 8.0, mode 12). The mean dose per treatment was 310.9 mC (s.d. = 191.9; median 262.6, mode 200.0 mC). Again, the difference between mean and median and mode indicates a right-skewed distribution. The total treatment series cumulative dose was 2915.3 mC (s.d. = 2889.0; median 2141.5, mode 550 mC). This again reflected a right-skewed distribution, with most patients receiving 12 treatments with a total treatment series dose of 550 mC.

The total response rate for ECT was 73% (\geq 50% reduction in MADRS score from pre-ECT baseline) and the remission rate was 51% (final MADRS score \leq 10). Changes in scoring of individual MADRS items are summarised in Table 2.

As the remission rate was close to 50%, MADRSRemission was used as the post-ECT outcome variable for individual patient predictions, as this allowed minimal exclusion of data in the larger

Variable	Entry values (MEn1–Men10)		Exit values (MEx1–MEx10)		7-test		
	Mean	s.d.	Mean	s.d.	Т	d.f.	Sig (2-tailed
MADRS individual item scores							
1 Apparent sadness	4.48	1.36	1.38	1.53	68.74	1983	< 0.001
2 Reported sadness	4.59	1.33	1.53	1.61	68.55	1980	< 0.001
3 Inner tension	4	1.39	1.6	1.46	56.96	1979	< 0.001
4 Sleep difficulties	3.04	1.83	0.99	1.37	44.41	1976	< 0.001
5 Appetite difficulties	3.32	1.9	0.9	1.37	50.72	1985	< 0.001
6 Concentration difficulties	4.12	1.26	1.79	1.49	56.34	1982	< 0.001
7 Lassitude	4.09	1.38	1.48	1.52	60.81	1982	< 0.001
8 Anhedonia	4.19	1.26	1.48	1.49	64.06	1980	< 0.001
9 Pessimistic thoughts	4.07	1.53	1.44	1.53	57.54	1977	< 0.001
10 Suicidal thoughts	3.06	1.75	0.94	1.33	50.72	1970	< 0.001
Total MADRS score	38.88	8.62	13.56	11.74	80.88	1985	< 0.001

MADRS, Montgomery-Asberg Depression Rating Scale; ECT, electroconvulsive therapy; d.f., degrees of freedom; Sig, significan

group. Clinically, achieving remission is important for minimising the risk of relapse.¹⁹

Group-level association analyses

Using simple linear regression, the final MADRS score (MADRSexit) was significantly negatively associated (Table 3) with age (Age_years_at_episode), total change in MADRS score (MADRSchange), presence of psychotic symptoms (PsychoticSx) and two of the reported indications for ECT: psychotic symptoms (IndPsycot) and previous good response to ECT (IndGoodResp). The final MADRS score (MADRSexit) was significantly positively associated with consent status (Informal), MADRS score before ECT (MADRSentry), Clinical Global Impression-Improvement score after two treatments (CGI-I2), total number of treatments (TreatmentsTotal) and total ECT dose over the full episode (EpisodeDoseTotal). For individual items on the MADRS, significant positive associations were found for reported sadness (MEn2), inner tension (MEn3), reduced sleep (MEn4) and suicidal thoughts (MEn10). Significant positive associations were also found for medication resistance (IndMedResis; IndMedResis1 [antidepressants]; IndMedResis2 [antipsychotics]; IndMedResis3 [mood stabilisers]) and risk of suicide (IndSuicide). This means that better outcome (lower MADRSexit) was associated with older age, presence of psychotic symptoms, sadness, inner tension, reduced sleep, suicidal thoughts, previous good ECT response, being a detained patient, clear improvement after two treatments and lower total ECT dose.

For the post-ECT dichotomous variables MADRSResponder and MADRSRemission (Table 4; Supplementary Table 4a available at https://doi.org/10.1192/bjp.2024.126), simple logistic regression found significant associations between MADRSResponder and measures of Clinical Global Impression (CGIEntry, CGI-I2), ECT treatment (TreatmentsTotal, EpisodeDoseTotal), age (Age_years_at_ episode), consent status (Informal, Capacity_Consent), presence of psychotic symptoms (PsychoticSx), specific indications for ECT (urgent necessity [IndEmergency]; severe distress [IndDistressed]; psychomotor retardation [IndSevereRetard]; psychotic symptoms [IndPsycot]; medication resistance (IndMedResis, IndMedResis1 [antidepressants], IndMedResis3 [mood stabilisers]); and previous good response to ECT [IndGoodResp]), the entry MADRS scores (MADRSEntry), all individual items on the MADRS entry assessment with the exception of reduced sleep and suicidal ideation (i.e. not MEn4 or MEn10), and the change in MADRS score following treatment (MADRSChange).

MADRSRemission was significantly associated with the Clinical Global Impression-Improvement score after two

Factor	Т	Р
Negative association with MADRSexit	score	
Age_years_at_episode	-6.97	<0.001*
Female	-1.45	0.146
CGIEntry	-0.26	0.80
MADRSchange	-56.78	<0.001*
Episode_mean_dose_per_treatment	-0.42	0.67
MEn1 – apparent sadness	-0.53	0.60
IndDistressed	-1.79	0.074
IndEmergency	-0.53	0.595
IndGoodResp	-4.53	<0.001*
IndPsycot	-2.54	0.011*
IndSevereRetard	-1.86	0.062
PsychoticSx	-3.62	<0.001*
RecurrentDD	-1.20	0.229
Positive association with MADRSexit s	core	
CGI-I2	7.66	<0.001*
MADRSentry	4.09	<0.001*
TreatmentsTotal	3.78	<0.001*
EpisodeDoseTotal	2.25	0.025*
Informal	2.81	0.005*
MEn2 – reported sadness	3.15	0.002*
MEn3 – inner tension	2.63	0.009*
MEn4 – reduced sleep	2.64	0.008*
MEn5 – reduced appetite	1.4	0.16
MEn6 – concentration difficulties	1.26	0.21
MEn7 – lassitude	1.25	0.21
MEn8 – inability to feel	1.63	0.10
MEn9 – pessimistic thoughts	1.48	0.14
MEn10 – suicidal thoughts	7.57	<0.001*
IndMedResis	5.03	<0.001*
IndMedResis1	5.10	<0.001*
IndMedResis2	2.05	0.041*
IndMedResis3	4.16	<0.001*
IndPatPref	0.51	0.609
IndSuicide	3.68	<0.001*
MADRSexit, total score on the Montgomery–Åsberg from the course of electroconvulsive therapy.	g Depression Rating S	Scale on exit

 Table 3
 MADRSexit^a associations using simple linear regression

from the course of electroconvulsive therapy. a. Low MADRSexit scores correspond to low levels of depressive symptoms. For definitions of other individual variables see Table 1 * Significant at P < 0.05

(CGI-I2), ECT treatment (TreatmentsTotal, treatments EpisodeDoseTotal), age (Age_years_at_episode), consent status (Informal, Capacity_Consent), presence of psychotic symptoms (PsychoticSx), history of recurrent depression (RecurrentDD), specific indications for ECT (severe distress [IndDistressed]; risk of suicide [IndSuicide]; psychomotor retardation [IndSevereRetard]; psychotic symptoms [IndPsycot]; medication resistance (IndMedResis, IndMedResis1 [antidepressants], IndMedResis3

550

	Res	sponse	Remission		
Factor	OR	Р	OR ^b	Р	
CGIEntry	1.23	0.001*	1.08	0.15	
CGI-12	0.6	<0.001*	0.63	< 0.00	
TreatmentsTotal	0.98	0.026	0.95	< 0.00	
pisodeDoseTotal	1	0.051	1	0.00	
pisode_mean_dose_per_treatment	1	0.85	1	0.7	
Age_years_at_episode	1.02	<0.001*	1.02	<0.00	
emale	1.12	0.3	1.18	0.07	
Capacity_Consent	1.14	<0.001*	1.12	<0.00	
formal	0.62	<0.001*	0.71	<0.00	
rsychoticSx	1.53	<0.001*	1.48	<0.00	
lecurrentDD	1.16	0.15	1.21	0.03	
ndEmergency	1.6	0.024*	1.31	0.0	
ndDistressed	1.77	<0.001*	1.27	0.01	
ndSevereRetard	1.38	0.01*	1.38	0.00	
ndSuicide	0.95	0.67	0.72	<0.00	
ndPsycot	1.4	0.008*	1.39	0.00	
ndMedResis – medication resistance	0.59	<0.001*	0.63	<0.00	
ndMedResis1 – antidepressants	0.6	<0.001*	0.63	<0.00	
ndMedResis2 – antipsychotics	0.81	0.07	0.91	0.39	
ndMedResis3 – mood stabilisers	0.56	<0.001*	0.68	0.00	
ndPatPref	0.97	0.77	0.89	0.20	
ndGoodResp	1.33	0.006*	1.45	<0.00	
/ADRSEntry	1.03	<0.001*	0.99	0.02	
1En1 – apparent sadness	1.23	<0.001*	1.06	0.09	
NEn2 – reported sadness	1.11	0.006*	0.93	0.04	
/En3 – inner tension	1.1	0.008*	0.95	0.08	
/En4 – reduced sleep	1.05	0.065	0.94	0.01	
1En5 – reduced appetite	1.11	<0.001*	1	0.99	
1En6 – concentration difficulties	1.16	<0.001*	1.01	0.69	
1En7 – lassitude	1.15	<0.001*	1	0.90	
1En8 – inability to feel	1.16	<0.001*	0.97	0.3	
1En9 – pessimistic thoughts	1.14	<0.001*	1	0.98	
1En10 – suicidal thoughts	0.96	0.18	0.83	<0.00	

b. An odds ratio $OR \ge 1.0$ indicates a positive association. * Significant at P < 0.05.

[mood stabilisers]); and previous good response to ECT [IndGoodResp]), the entry MADRS scores (MADRSEntry), specific items on the MADRS entry assessment (reported sadness [MEn2]; reduced sleep [MEn4]; and suicidal thoughts [MEn10]) and the change in MADRS score following treatment (MADRSChange).

Individual patient prediction analyses for remission (Fig. 1)

For machine learning prediction we used the SVM algorithm with a linear kernel within NeuroMiner. No feature reduction method was used, and when this was explored, no benefit was found. To get an accurate representation of the true accuracy of our model, we used a 10-fold nested cross-validation (10-fold inner and 10-fold outer) with the hyperparameter tuning done in an automated fashion (as already coded within NeuroMiner) within the inner folds to avoid any potentiation overfitting and we used a fixed random seed value of 654.

The variables we used for prediction were not related to final outcomes measures - they were pre-ECT variables and degree of improvement after two ECT treatments (Table 1). For model 1 these were CGIEntry, MADRSEntry, Age_years_at_episode, Female, Capacity_Consent, Informal, PsychoticSx, RecurrentDD, IndEmergency, IndDistressed, IndSevereRetard, IndSuicide, IndPsycot, IndMedResis, IndMedResis1, IndMedResis2, IndMedResis3, IndPatPref and IndGoodResp. The individual patient predictive accuracy for model 1 was 60.4%, sensitivity 58.5%, specificity 62.2% and AUC 0.63 (95% CI 0.61-0.66). For model 2 the pre-ECT variables used were CGIEntry, CGII2,

MADRSEntry, Age_years_at_episode, Female, Capacity_Consent, Informal, PsychoticSx, RecurrentDD, IndEmergency, IndDistressed, IndSevereRetard, IndSuicide, IndPsycot, IndMedResis, IndMedResis1, IndMedResis2, IndMedResis3, IndPatPref and IndGoodResp. The individual patient predictive accuracy for model 2 was 61%, sensitivity 56.3%, specificity 65.3% and AUC 0.65 (95% CI 0.62-0.68). For this more accurate model the positive predictive value (PPV) was 60.9% and the negative predictive value (NPV) was 61.2% (for additional details see the Supplementary Material).

Discussion

Using 10 years of SEAN ECT data we tested two hypotheses. First, that that there were significant group-level associations between post-ECT clinical outcomes and clinical variables available before starting a course of ECT. A range of group-level associations were found. Second, that it was possible to develop a new method for predicting illness remission for individual patients using machine learning. We found it possible to predict individual patient remission with ECT to an accuracy of 61% for moderate to severe acute unipolar depression, despite ECT being an already very effective treatment for such illness.

Group-level associations with final outcome

Our sample of patients was selected as having moderate to severe symptoms of depression, meaning an average MADRS baseline (pre-ECT) score of 38.8. We found that the final (post-ECT




Fig. 1 Mean classifier scores for support vector machine (SVM) modelling and receiver operator curve (ROC) analysis from model 1 ((a) and (b)) and model 2 ((c) and (d)) for individual patient prediction of remission.

course) MADRS score was associated with the total MADRS baseline score and baseline MADRS item scores for sadness, inner tension, reduced sleep and suicidal thoughts. Response (≥50% reduction in baseline MADRS score) was significantly associated with baseline MADRS scores for all items except reduced sleep and suicidal thoughts. Remission (final MADRS score ≤10) was associated with baseline MADRS scores for sadness, reduced sleep and suicidal thoughts. Other baseline items, such as being detained under the Mental Health Act, presence of psychotic symptoms, severe distress and psychomotor retardation, were significantly associated with ECT efficacy - i.e. response and remission. This is broadly consistent with a recent meta-analysis⁹ which reported that ECT was more effective in patients with depression with psychotic features, in those with more severe depression and in older patients. Older age has long been recognised as being associated with better response to ECT^{8,21} and with remission.⁹

A recent report utilising the Global ECT-MRI Research Collaboration (GEMRIC) data-set²² found that, in 500 people with major depressive disorder, remission rates with ECT were independent of gender. Van Diermen et al⁹ did not specifically examine gender, since a previous meta-analysis by Haq et al²³ found that gender (along with bipolar diagnosis, age at onset and number of previous episodes) did not significant predict the efficacy of ECT. However, there is significant heterogeneity in the pooled data of these meta-analyses. Our study is more homogeneous and specifically examined only moderate to severe unipolar depressive episodes. In this population, even though approximately two-thirds of our 2074 patients were female, we confirmed that ECT outcomes are independent of gender.

We found that the presence of antidepressant treatment resistance was associated with poorer ECT response, similar to a recent large Swedish National Quality Register for ECT study (n = 4244) that compared outcomes for patients meeting criteria for treatment resistant (TRD) or non-treatment resistant depression (non-TRD) and found them to be lower for the TRD group compared with the non-TRD group.²⁴ Previous meta-analyses have also found the absence of medication failure to be associated with better ECT outcomes.^{23,25} Patients who do not respond to ECT may have subtle genetic differences compared with those who respond.^{26,27}

There are few studies that have specifically looked at ECT outcomes based on single-episode versus recurrent depressive disorder. Our data support a history of recurrent depression being associated with remission but not response. This is supported by a metaanalysis²³ in which the number of previous depressive episodes was not significantly associated with response, as well as studies examining recurrence of depression in individuals in remission who discontinued ECT, which reported shorter time to relapse associated with the number of previous depressive episodes²⁸ and an association between risk of relapse and greater number of previous ECT courses.²⁹ Taken together, these studies suggest that individuals with recurrent depression constitute a cohort who are likely to respond very well to ECT and may require repeated courses or maintenance ECT.

Many national guidelines, including those of the Royal College of Psychiatrists in the UK,³⁰ recommend ECT as a first-line treatment in people with depression who require emergency treatment owing to the risk to physical health and/or high suicide risk, because of ECT's efficacy and speed of action.³¹ The findings

from linked registry data of the Swedish National Quality Register for ECT and the Swedish National Inpatient Register (n = 5525 individuals with depression treated with or without ECT) support ECT as being significantly associated with a decreased risk of suicide in in-patients who are severely depressed, especially those who are older than 45 years and those with a psychotic subtype.³² A large Canadian retrospective cohort study of records of people admitted to psychiatric hospital for depression (n = 67327) reported that ECT was associated with a significantly reduced risk of death by suicide in the year after discharge.33 In our analyses suicidal thoughts on individual MADRS symptom scoring (MEn10) and suicide as a recorded indication for ECT (IndSuicide) were not associated with treatment response and were negatively associated with remission of symptoms; however, ECT improved (Table 2) all baseline MADRS symptoms. Urgent necessity (IndEmergency) was associated with response but not remission, and severe distress as an indication for ECT (IndDistressed) was associated with both response and remission.

We found that patient preference was not a predictor of either response or remission, consistent with previous reports,^{34,35} which implies that patient expectation is not a significant factor (placebo effect) affecting outcome. We found that patients detained under the Mental Health Act were more likely to be MADRS responders or remitters, perhaps because detention was associated with illness severity, severe distress or potential risk of dying.³⁶

Early response associations and predictions

Studies have shown that early improvement after six^{37–39} or three^{40,41} ECT sessions was associated with final outcome. A 15% reduction in MADRS score after two sessions of ECT was reported to predict final remission with modest sensitivity (51%) and better specificity (79%).⁴² The SEAN data-set does not include ratings for depression symptoms throughout the course of ECT but does include the Clinical Global Impression-Improvement rating after the second treatment and at the end of treatment. Previous relatively small studies utilising CGI-I scores in adolescents⁴³ and adults⁴⁴ did not report clear associations with outcomes, although later CGI scores were associated with good final outcomes. We found that the CGI-I2 score (rated after just two treatments) was significantly correlated with final (post-ECT course) MADRS scores.

Individual patient predictions of outcome

There are very few studies that have tried to create a clinically applicable prediction model for ECT efficacy. De Vreede et al⁴⁵ used multivariable analyses to derive a simple index of four independent predictors (age >65 years, psychotic depression, refractory to antidepressant medication, and personality disorder) which predicted good response (reduction in Hamilton Rating Scale for Depression score of \geq 50% compared with baseline) with an AUC of 0.76. However, accuracy of individual patient predictions was not provided nor was cross-validation used. Based on the response prediction literature, as well as clinical experience, Kellner et al⁸ proposed a 3-item appropriateness scale for ECT that included depression severity, heritability and the episodic nature of depression. However, this model has not been validated in a patient sample. Using an adapted Maudsley Staging Method (MSM), van Diermen et al⁴⁶ found that depressive episode duration alone was the best predictor of remission (as defined by a score on the 17item Hamilton Rating Scale for Depression of ≤7) after ECT (AUC = 0.72). However, cross-validation was not used and hence results are likely to be overestimates.

Several studies have applied machine learning models to the prediction of ECT outcomes, usually using neuroimaging data.^{47–54} A recent study used Global ECT-MRI Research Collaboration (GEMRIC) data to predict remission using a combination of grey matter volume and functional connectivity measures in a training set of 189 people with depression, resulting in 0.70-0.73 AUC crossvalidation accuracy55 for predicting response. Nakajima et al56 reported a model based on clinical information, finding that shorter duration of the current illness episode, lower baseline depression severity, higher dose of antidepressant medications before ECT and lower body mass index predicted remission following ECT with 71% accuracy (sensitivity of 86%, and specificity of 46%). Although cross-validation was used, their study was limited by remission being evaluated retrospectively using the c-CGI (a 4-point clinical note CGI-Improvement scale), and clinical heterogeneity, as both bipolar and unipolar depression were included. Our study addressed some of these limitations by its larger large sample size, clinical homogeneity and use of prospective MADRS and CGI scores, finding a cross-validated accuracy of 61% for predicting remission.

It is worth noting that the reason for including machine learning was to demonstrate that it is possible to make predictions for individual patient ECT outcomes from the available data, i.e. that the baseline data collected by SEAN contain sufficient information to allow this. It was not to suggest that this should be introduced into clinical practice. Prediction methods cannot be introduced into clinical practice without prospective clinical trials (as with new drugs), given the potential for harm

Strengths

Retrospective, observational analysis of routinely collected clinical data, such as our use of the SEAN data-set, can achieve much larger sample sizes than would be feasible in a randomised controlled trial (RCT) and may better reflect clinical practice. Analyses also have sufficient statistical power to draw more meaningful conclusions regarding associations and allow utilisation of predictive modelling with cross-validation.

Limitations

Data acquired across multiple geographical locations and over a 10year period may include unknown heterogeneity that the use of standardised assessment instruments, such as ICD-10 coding of diagnosis, MADRS for clinical severity and CGI for severity and improvement measures, will minimise to some extent. However, this may be a strength, as SEAN data reflect actual clinical practice.

The data provided by SEAN is for episodes of treatment, meaning we do not know how often individual patients appear in the data-set, which might inflate the results if patients having a previously good response are more likely to have multiple treatments. However, our reported remission rate of 51% is very similar to other studies, such as van Diermen et al's recent meta-analysis⁹ in which the remission rate was 57.8% for patients with depression and psychotic symptoms and 50.9% for those without psychotic symptoms. Analyses could only be done using the pre-specified SEAN data fields, and other clinical data not included in our SEAN data request may be relevant for response and remission, for example electrode position,⁵⁷ anaesthetic agents^{58,59} or the number of ECT treatments in a course.⁹ Although these factors have the potential to influence the efficacy of ECT they were not individual patient baseline (pre-ECT) factors.

Conclusions and clinical implications

Using a decade of national SEAN data we report a number of grouplevel associations between baseline patient characteristics and clinical outcomes, including response and remission, consistent with previous studies. ECT response was associated with older age, psychotic symptoms, necessity for urgent intervention, severe distress, psychomotor retardation, previous good response, lack of medication resistance and lack of capacity to consent. Remission had the same associations, except for urgent necessity and in addition a history of recurrent depression and low suicide risk. ECT is a very effective treatment for moderate to severe depressive illness and is associated with a response rate of 73% and a remission rate of 51%. Despite the high efficacy of ECT as a treatment, we were able to predict individual patient remission using routinely collected SEAN baseline clinical data with an accuracy of 60% (model 1), rising to 61% (model 2) with the inclusion of an early measure of treatment response obtained after the first two treatments (CGI-I2). The use of a predictive tool could help inform the shared treatment decision-making process and prevent both the unnecessary use of ECT when it is unlikely to be of clinical benefit and the unnecessary delay in commencing ECT when it is likely to be most effective.

David M. Semple , University Hospital Hairmyres, NHS Lanarkshire, Glasgow, UK; Szabolcs Suveges, School of Medicine, University of Dundee, Dundee, UK; J. Douglas Steele , School of Medicine, University of Dundee, Dundee, UK

Correspondence: David Semple. Email: dsemple2@ed.ac.uk

First received 31 Jan 2024, final revision 24 Jul 2024, accepted 29 Jul 2024

Supplementary material

Supplementary material is available online at https://doi.org/10.1192/bjp.2024.126.

Data availability

The data that support the findings of this study are available on request from the corresponding author D.M.S., following appropriate permissions being obtained from the Scottish National Audit Programme of Public Health Scotland and the Scottish ECT Audit Network.

Acknowledgements

We thank the Scottish ECT Accreditation Network (SEAN) Steering Group for approving our use of the SEAN data-set. In addition, we thank data analyst David Murphy at Public Health Scotland for his work in extracting anonymised data.

Author contributions

D.M.S. and J.D.S. formulated the research questions, designed the study, analysed the data and wrote the article. S.S. contributed to the statistical analysis and machine learning prediction analyses, which used NeuroMiner.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

None.

References

- 1 Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study. J Psychiatr Res 2020; 126: 134–40.
- 2 Rush AJ, Kilner J, Fava M, Wisniewski SR, Warden D, Nierenberg AA, et al. Clinically relevant findings from STAR*D. Psychiatr Ann 2008; 38: 188–93.
- 3 Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004; 20: 13–20.
- 4 Group UER. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; 361: 799–808.
- 5 Rosenquist PB, Brenes GB, Arnold EM, Kimball J, McCall WV. Health-related quality of life and the practice of electroconvulsive therapy. J ECT 2006; 22: 18–24.

- 6 Buley N, Copland E, Hodge S, Chaplin R. A further decrease in the rates of administration of electroconvulsive therapy in England. J ECT 2017; 33: 198–202.
- 7 Fergusson GM, Cullen LA, Freeman CP, Hendry JD. Electroconvulsive therapy in Scottish clinical practice: a national audit of demographics, standards, and outcome. J ECT 2004; 20: 166–73.
- 8 Kellner CH, Popeo DM, Pasculli RM, Briggs MC, Gamss S. Appropriateness for electroconvulsive therapy (ECT) can be assessed on a three-item scale. *Med Hypotheses* 2012; **79**: 204–6.
- 9 van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. *Br J Psychiatry* 2018; 212: 71–80.
- 10 Scottish ECT Accreditation Network. Scottish ECT Accreditation Network (SEAN): 2021 (Reporting on 2020 Data). Public Health Scotland, 2021 (https://www.publichealthscotland.scot/media/10034/sean_2021_ management_information_report.pdf).
- 11 World Health Organization. *Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-10 Chapter V, Primary Care Version*. Hogrefe & Huber Publishers, 1996.
- 12 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
- 13 Muller MJ, Szegedi A, Wetzel H, Benkert O. Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord 2000; 60(2): 137–40.
- 14 Poldrack RA, Huckins G, Varoquaux G. Establishment of best practices for evidence for prediction: a review. JAMA Psychiatry 2020; 77: 534–40.
- 15 Steele JD, Paulus MP. Pragmatic neuroscience for clinical psychiatry. Br J Psychiatry 2019; 215: 404–8.
- 16 Varga TV, Niss K, Estampador AC, Collin CB, Moseley PL. Association is not prediction: a landscape of confused reporting in diabetes – a systematic review. *Diabetes Res Clin Pract* 2020; 170: 108497.
- 17 JASP Team. JASP [computer program]. JASP, 2023 (https://jasp-stats.org/).
- 18 Koutsouleris N, Vetter C, Wiegand A. Neurominer [computer software]. Section for Neurodiagnostic Applications, Ludwig-Maximillian-University of Munich, 2022 (http://www.proniapredictors.eu/neurominer/index.html).
- 19 Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. *Psychol Med* 1995; 25(6): 1171–80.
- 20 Wu O. Rethinking class imbalance in machine learning. arXiv [cs.LG] [Preprint] 2023. Available from: https://arxiv.org/abs/2305.03900.
- 21 Waite S, Tor PC, Mohan T, Davidson D, Hussain S, Dong V, et al. The utility of the Sydney Melancholia Prototype Index (SMPI) for predicting response to electroconvulsive therapy in depression: a CARE network study. J Psychiatr Res 2022; 155: 180–5.
- 22 Blanken M, Oudega ML, Hoogendoorn AW, Sonnenberg CS, Rhebergen D, Klumpers UMH, et al. Sex-specifics of ECT outcome. J Affect Disord 2023; 326: 243–8.
- 23 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. *J Clin Psychiatry* 2015; 76: 1374–84.
- 24 Nygren A, Reutfors J, Brandt L, Boden R, Nordenskjold A, Tiger M. Response to electroconvulsive therapy in treatment-resistant depression: nationwide observational follow-up study. *BJPsych Open* 2023; 9(2): e35.
- 25 Heijnen WT, Birkenhager TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol 2010; 30: 616–9.
- 26 Clements CC, Karlsson R, Lu Y, Jureus A, Ruck C, Andersson E, et al. Genomewide association study of patients with a severe major depressive episode treated with electroconvulsive therapy. *Mol Psychiatry* 2021; 26: 2429–39.
- 27 Foo JC, Streit F, Frank J, Witt SH, Treutlein J, Major Depressive Disorder Working Group of the Psychiatric Genomics C, et al. Evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy. *Am J Med Genet B Neuropsychiatr Genet* 2019; **180**: 35–45.
- 28 Yang WC, Lin CH, Chen CC. Risk factors of relapse after successful electroconvulsive therapy for Taiwanese patients with major depression. *J ECT* 2020; 36: 106–10.
- 29 Lambrichts S, Vansteelandt K, Crauwels B, Obbels J, Pilato E, Denduyver J, et al. Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic. Acta Psychiatr Scand 2021; 144: 230–7.
- 30 Royal College of Psychiatrists. Electroconvulsive Therapy Information Resource. RCPsych, 2022 (https://www.rcpsych.ac.uk/mental-health/ treatments-and-wellbeing/ect).
- 31 Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004; 65: 485–91.

- 32 Ronnqvist I, Nilsson FK, Nordenskjold A. Electroconvulsive therapy and the risk of suicide in hospitalized patients with major depressive disorder. *JAMA Netw Open* 2021; 4(7): e2116589.
- 33 Kaster TS, Blumberger DM, Gomes T, Sutradhar R, Wijeysundera DN, Vigod SN. Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. *Lancet Psychiatry* 2022; 9: 435–46.
- 34 Brodaty H, Berle D, Hickie I, Mason C. Perceptions of outcome from electroconvulsive therapy by depressed patients and psychiatrists. *Aust N Z J Psychiatry* 2003; 37: 196–9.
- 35 Iltis AS, Fortier R, Ontjes N, McCall WV. Ethics considerations in laws restricting incapacitated patients' access to ECT. J Am Acad Psychiatry Law 2023; 51: 47–55.
- **36** Salagre E, Rohde C, Ishtiak-Ahmed K, Gasse C, Ostergaard SD. Survival rate following involuntary electroconvulsive therapy: a population-based study. *J ECT* 2021; **37**: 94–9.
- 37 Lin CH, Chen MC, Yang WC, Lane HY. Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy. *Eur Neuropsychopharmacol* 2016; 26: 225–33.
- 38 Lin HS, Lin CH. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT. J Affect Disord 2019; 245: 91–7.
- 39 Martinez-Amoros E, Goldberg X, Galvez V, de Arriba-Arnau A, Soria V, Menchon JM, et al. Early improvement as a predictor of final remission in major depressive disorder: new insights in electroconvulsive therapy. J Affect Disord 2018; 235: 169–75.
- **40** Zheng W, He M, Gu LM, Lao GH, Wang DF, Mai JX, et al. Early improvement as a predictor of final remission in patients with treatment-resistant depression receiving electroconvulsive therapy with ketofol anesthesia. *J Affect Disord* 2022; **310**: 223–7.
- 41 Tsuchiyama K, Nagayama H, Yamada K, Isogawa K, Katsuragi S, Kiyota A. Predicting efficacy of electroconvulsive therapy in major depressive disorder. *Psychiatry Clin Neurosci* 2005; 59: 546–50.
- 42 Birkenhager TK, Roos J, Kamperman AM. Improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression. *Acta Psychiatr Scand* 2019; **140**: 189–95.
- 43 Maoz H, Nitzan U, Goldwyn Y, Krieger I, Bloch Y. When can we predict the outcome of an electroconvulsive therapy course in adolescents? A retrospective study. J ECT 2018; 34: 104–7.
- 44 Chen CC, Lin CH, Yang WC, Chen MC. Clinical factors related to acute electroconvulsive therapy outcome for patients with major depressive disorder. Int Clin Psychopharmacol 2017; 32: 127–34.
- 45 de Vreede IM, Burger H, van Vliet IM. Prediction of response to ECT with routinely collected data in major depression. J Affect Disord 2005; 86: 323–7.
- 46 van Diermen L, Hebbrecht K, Schrijvers D, Sabbe BCG, Fransen E, Birkenhager TK. The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression. Acta Psychiatr Scand 2018; 138: 605–14.

- 47 Jiang R, Abbott CC, Jiang T, Du Y, Espinoza R, Narr KL, et al. SMRI biomarkers predict electroconvulsive treatment outcomes: accuracy with independent data sets. *Neuropsychopharmacology* 2018; **43**: 1078–87.
- **48** Leaver AM, Wade B, Vasavada M, Hellemann G, Joshi SH, Espinoza R, et al. Fronto-temporal connectivity predicts ECT outcome in major depression. *Front Psychiatry* 2018; **9**: 92.
- 49 Mulders PCR, Llera A, Beckmann CF, Vandenbulcke M, Stek M, Sienaert P, et al. Structural changes induced by electroconvulsive therapy are associated with clinical outcome. *Brain Stimul* 2020; **13**: 696–704.
- 50 Redlich R, Opel N, Grotegerd D, Dohm K, Zaremba D, Burger C, et al. Prediction of individual response to electroconvulsive therapy via machine learning on structural magnetic resonance imaging data. JAMA Psychiatry 2016; 73: 557–64.
- 51 Takamiya A, Liang KC, Nishikata S, Tarumi R, Sawada K, Kurokawa S, et al. Predicting individual remission after electroconvulsive therapy based on structural magnetic resonance imaging: a machine learning approach. *J ECT* 2020; 36: 205–10.
- 52 van Waarde JA, Scholte HS, van Oudheusden LJ, Verwey B, Denys D, van Wingen GA. A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. *Mol Psychiatry* 2015; 20: 609–14.
- 53 Wade BSC, Hellemann G, Espinoza RT, Woods RP, Joshi SH, Redlich R, et al. Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy. *Hum Brain Mapp* 2021; 42: 5322–33.
- 54 Wang J, Wei Q, Yuan X, Jiang X, Xu J, Zhou X, et al. Local functional connectivity density is closely associated with the response of electroconvulsive therapy in major depressive disorder. J Affect Disord 2018; 225: 658–64.
- 55 Bruin WB, Oltedal L, Bartsch H, Abbott C, Argyelan M, Barbour T, et al. Development and validation of a multimodal neuroimaging biomarker for electroconvulsive therapy outcome in depression: a multicenter machine learning analysis. *Psychol Med* 2024: 54: 495–506.
- 56 Nakajima K, Takamiya A, Uchida T, Kudo S, Nishida H, Minami F, et al. Individual prediction of remission based on clinical features following electroconvulsive therapy: a machine learning approach. J Clin Psychiatry 2022; 83(5): 21m14293.
- 57 Semkovska M, Landau S, Dunne R, Kolshus E, Kavanagh A, Jelovac A, et al. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. *Am J Psychiatry* 2016; **173**: 408–17.
- 58 Lihua P, Su M, Ke W, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. *Cochrane Database Syst Rev* 2014; 2014(4): CD009763.
- 59 Galvez V, McGuirk L, Loo CK. The use of ketamine in ECT anaesthesia: a systematic review and critical commentary on efficacy, cognitive, safety and seizure outcomes. *World J Biol Psychiatry* 2017; 18: 424–44.

